Aims Cardiac biomarkers are routinely elevated after uncomplicated cardiac surgery to levels considered diagnostic of myocardial infarction in ambulatory populations. We investigated the diagnostic power of electrocardiogram (ECG) and cardiac biomarker criteria to predict clinically relevant myocardial injury using benchmarks of mortality and increased hospital length of stay (HLOS) in patients undergoing coronary artery bypass graft (CABG) surgery.
Introduction
Perioperative myocardial infarction (PMI) occurs in 7-15% of patients after cardiac surgery and is associated with increased hospital length of stay (HLOS), costs, and reduced short-and longterm survival. 1 -4 In non-surgical populations, myocardial infarction (MI) is diagnosed with a combination of clinical symptoms, elevation of cardiac-specific biomarkers, and electrocardiographic (ECG)
pattern. However, the determination of PMI after cardiac surgery is problematic because of the absence of a diagnostic 'gold standard'. Even after uncomplicated cardiac surgery, the high frequency of indeterminate diagnostic ECG criteria and routine elevation of cardiac-specific biomarkers to levels considered diagnostic of MI in ambulatory populations makes the diagnosis of PMI challenging. 1 In 2007, the Joint Task Force of the European Society of Cardiology/American College of Cardiology for the 'Redefinition of Myocardial Infarction' defined PMI using a combination of biomarker elevation and ECG, imaging, or angiography. 5 Despite a lack of supportive evidence, the Task Force chose a cut-off for biomarker diagnosis of PMI at five times the upper limit of laboratory normal (ULN) within the first 72 h after surgery, when associated with the appearance of new pathological Q-waves or new LBBB. However, the recommendations of the consensus committee have not been consistently validated, 1, 6, 7 are unproven in cardiac surgical populations, 8 and have been the controversial subject of numerous editorials. 9 -11 Therefore, utilizing a primary test cohort and a validation cohort of patients undergoing primary coronary artery bypass grafting (CABG), we assessed the predictive value of cardiac troponins I and T (cTnI and cTnT), the MB fraction of creatinine kinase (CKMB), and ECG criteria to predict the risk of 5-year mortality and increased HLOS.
Methods

Primary test cohort
The primary test cohort was obtained from a prospective longitudinal parent study of 1447 patients undergoing primary CABG surgery with cardiopulmonary bypass (CPB) between August 2001 and May 2006 at Brigham and Women's Hospital, Boston, MA, USA ( Table 1) (CABG Genomics Program; website: http://clinicaltrials.gov/show/ NCT00281164). With Institutional Review Board approval (IRB), written informed consent was obtained from each patient. Patients were excluded from the parent study if they were less than 20 years old; underwent repeat, off-pump CABG, concomitant valve or other cardiac surgery; had a pre-operative haematocrit , 25%, or if they had received leucocyte rich blood products within 30 days prior to surgery. Patients were further excluded from analysis if they had a preoperative MI within 2 weeks of surgery or had missing perioperative ECG or biomarker data (CONSORT Diagram Figure 1 ). Patients underwent CPB with extracorporeal circulation using a single aortic cross-clamp technique and cold-blood cardioplegia. Demographic data, past medical and surgical history, and medications were recorded by trained research staff using defined protocols in a purpose-built case report form. Patients were followed for up to 5 years from the date of surgery (mean follow-up + SD; 3.3 + 1.4 years).
Biomarker assays
Blood samples were drawn prior to the induction of general anaesthesia, after administration of post-CPB protamine, and on the mornings of POD1 -5. Patient caregivers were not aware of the results. Serum and plasma were stored in vapor-phase liquid nitrogen until analysis for cTnI and CKMB with a sandwich immunoassay on a Triage w platform using monoclonal and polyclonal antibodies (Biosite Inc., San Diego, CA) at a single core facility.
ECG data
Machine-generated ECG interpretations (Marquette 12SL, Mac 5500; GE Healthcare, Waukesha, MI, USA) were over-read by a board certified cardiologist taking into consideration prior ECGs when encountering new findings (bundle branch blocks, Q-waves) during the patient's hospital admission. Cardiologist over-reading has been shown to have high sensitivity and specificity. 12 
Clinical endpoints for the test cohort
The primary clinical endpoint was all-cause mortality occurring up to 5 years after surgery. Mortality data was obtained from the social security death index. The secondary endpoint was HLOS measured in days, and included the date of surgery and date of discharge as complete days of stay. In order to establish the value of adding biomarkers to an established risk prediction model, an individual risk score was calculated for each patient using the Euroscore logistic model. 14 Each biomarker, as well as each ECG criterion, was then added individually to assess improvement of model performance.
Validation cohort
To validate both the primary and secondary endpoints in the primary cohort using a different population not included in the CABG Genomics Program, 
Statistical methods
Statistical analyses were performed using SAS, version 9. Biomarkers-pre-operative (ROC) curves in a multivariable model for mortality to confirm the optimal cut-point selection. F-tests were used to compare generalized r 2 . A two-sided P , 0.05 was considered significant.
The validation cohort was separately acquired after the original prospective trial and utilized only the clinical information routinely recorded by caregivers. Therefore, we performed a Cox proportional hazard model for mortality and HLOS using a minimized clinical model of age, gender, and race.
Results
Demographics and post-operative clinical outcomes were similar for the primary test and validation cohorts, except for a significantly younger population in the primary test population ( Table 1) . After applying exclusion criteria, 545 patients were analyzed in the test cohort and 1013 in the validation cohort.
Test cohort
The highest mean concentrations of CKMB and cTnI ( Figure 2) were measured on POD1 for 94% and 92% of patients, respectively, as has been previously shown. 16 The percentages of ECGs in each of the grades for PMI varied widely and are listed in Supplementary material online, Table S1 . Levels of CKMB and cTnI were different between patients diagnosed with PMI by ECG for the majority of the eight ECG criteria (Supplementary material online, Table S2 ).
Mortality
Pre-operative CKMB and cTnI did not independently predict mortality ( Table 2) . None of the eight ECG criteria independently Table 2) . The additional predictive value of POD1 biomarkers, over a clinical model that included demographics, pre-operative, and intraoperative variables were compared with the clinical model alone ( Table 3) . cTnI had the strongest association with 5-year mortality (P ¼ 0.039 compared with CKMB) and was significantly more robust than POD1 CKMB ( Figure 3 and Table 3 ). Similarly, when we accounted for the patients' clinical condition using the well-validated logistic Euroscore, cTnI improved prediction of 5-year mortality (P ¼ 0.023 compared with CKMB) ( Table 3 ). Inclusion of POD2 or POD3 biomarker data did not improve the prediction of mortality. Addition of POD1 CKMB to the Cox multivariable models for mortality, while independently significant, did not improve prediction over the model with POD1 cTnI alone. Furthermore, none of the eight ECG criteria for myocardial injury predicted mortality or improved prediction of 5-year mortality when added to cohortderived model or the logistic Euroscore (only last ECG is shown in Table 3 ) alone, or in combination with any biomarker.
Hospital length of stay
In the primary test cohort, pre-operative CKMB and cTnI did not independently predict HLOS ( Table 2 ). In contrast, POD1 cTnI and CKMB independently predicted an increased HLOS (Figure 3 ), even after adjusting for demographics, patient risk factors, and perioperative variables ( Figure 3 and Table 3 ). Addition of POD1 CKMB or cTnI to the logistic Euroscore significantly improved prediction of HLOS ( Table 3) . Inclusion of POD2 or POD3 biomarker data did not improve prediction of HLOS, when added to the logistic Euroscore. None of the eight ECG criteria predicted HLOS or improved prediction of HLOS by either model (Figure 3 ).
Validation cohort
To confirm the positive association between cardiac troponin and both 5-year mortality or HLOS in the primary test cohort, we examined the value of cardiac cTnT in an independently collected cardiac surgical population. In the validation cohort, POD1 cTnT was independently associated with 5-year mortality, even after adjusting for a minimized clinical model consisting of age, gender, and race (Supplementary material online, Table S3 ). Similarly, POD1 cTnT independently predicted HLOS (Supplementary material online, Table S3 ).
To confirm the utility of the minimized clinical model used in the validation cohort, the effect of biomarkers and ECG criteria were examined in the primary test cohort while adjusting for the minimized model. POD1 cTnI was significantly associated with an increase in mortality. Furthermore, inclusion of cTnI significantly improved overall model performance when predicting mortality (P , 0.001).
Dichotomization
A criterion of five times the ULN for biomarker assays, as proposed by the Joint Task Force as a measure of MI, 5 would have identified PMI in 96% of patients using cTnI, and 52% using CKMB in our primary test cohort. Similarly, 86% would have achieved a diagnosis of PMI using cTnT in the validation cohort. The dichotomization at the optimal ROC corresponds to a cTnI of 6. The clinical model contains only clinical predictors which vary for mortality (age, gender, race, hypertension, left ventricular ejection fraction, pre-operative haematocrit) and for HLOS (age, gender, race, pre-operative therapy with antiarrhythmics, digoxin, calcium channel blockers, platelet inhibitors, HMG Co-A reductase inhibitors, CPB duration). Dx 2 is comparable between models of the same patient number. The biomarker P-value denotes significance of the added variable, whereas the Nagelkerke r (69 patients) in the validation cohort. The unadjusted KaplanMeier significantly differentiates survival between those patients with a cTnI and cTnT below and above the cut-off in the test cohort [Hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.01-7.9; P , 0.05] as well as the validation cohort (HR 7.2, 95% CI 3.0 -17.3; P , 0.001) (Figure 4) .
When the dichotomized cTnI and cTnT are added to the multivariable clinical model unadjusted for length of survival, the AUC of the ROC improves from 0.807 to 0.815 in the test cohort and from 0.705 to 0.734 in the validation cohort. For patients above the cut-off, the mortality risk within 5 years of the operation is 1.7 (HR, 95% CI 1.1 -2.5; P ¼ 0.03) in the test cohort and 1.9 (HR, 95% CI 1.4 -2.5; P , 0.001) in the validation cohort, adjusted for length of survival.
Discussion
The definition of PMI after cardiac surgery remains controversial. We now demonstrate that: (i) the ECG diagnosis of perioperative myocardial injury or PMI after cardiac surgery does not predict post-operative mortality or HLOS; (ii) use of cTnI is a more robust predictor of mortality than CKMB; (iii) cTnI improves prediction of mortality and HLOS even when added to the wellvalidated and commonly used logistic Euroscore; and (iv) there is no incremental benefit when predicting 5-year mortality or HLOS by measuring cTnI after POD1. Together, these findings identify POD1 troponin as an important independent predictor of the clinical consequences of perioperative myocardial injury in patients undergoing CABG surgery. Moreover, these data suggest that the definition of PMI after cardiac surgery should be re-evaluated.
Q-waves and myocardial infarction
Electrocardiographic criteria considered to be diagnostic for MI, including non-specific non-Q-wave changes, are insensitive and not specific for PMI after CABG surgery. Aetiologies of ST-segment and T-wave changes can be due to electrolyte and conduction abnormalities, external cardiac pacing, and postsurgical pericarditis. 17 -19 New Q-waves were once considered the best measure of PMI after CABG surgery. 20, 21 However, recent studies have shown poor correlation between post-cardiac surgery Q-wave development and adverse cardiac outcomes. 1, 6, 22, 23 Notably, in a study of 785 primary CABG patients, Q-wave PMI was not an independent predictor of 30-day mortality, severe LV dysfunction, or both outcomes combined (P ¼ 0.17).
1
Others have also demonstrated that only 32% of patients in the upper quartile of cTnI actually have post-operative ischaemic ECG changes, and only 6% have new onset Q-waves. 2 
Biomarker elevation during cardiac surgery
After uncomplicated cardiac surgery, cardiac-specific biomarkers are routinely elevated to levels considered diagnostic of MI in ambulatory populations. 1 Perioperative elevation of cardiacspecific biomarkers may be due to PMI, but may also be associated with routine cardiac surgical procedures including transient myocardial ischaemia due to aortic occlusion or cardiotomy required for valve surgery. Our findings challenge the recommendations of the 2007 Joint Task Force of the ESC/ACCF/AHA/WHF for the Redefinition of Myocardial Infarction. These recommendations included a requirement for an elevation of cardiac enzymes, dichotomized at five times the ULN within the first 72 h after surgery, when associated with the appearance of new pathological Q-waves or new LBBB. 5 A criterion of five times the ULN for biomarker assays as a measure of significant myocardial injury would have identified PMI in 96% of patients using cTnI, and 52% using CKMB in our primary test cohort. Similarly, 86% would have achieved a diagnosis of PMI using cTnT in the validation cohort.
With ever increasing sensitivity of the biomarker assays, the ULN cut-offs would by definition include more patients and require constant readjustment. We therefore determined the optimal cut-off for cTnI and cTnT using a Cox proportional hazard model for mortality as well as ROC curves. In our cohorts, a cTnI of 6.9 mg/L and a cTnT of Figure 4 Kaplan-Meier survival for troponin dichotomized at optimal ROC. Shown are unadjusted all-cause survival curves for troponin at respective cut-offs. The optimal dichotomization point was determined in a Cox proportional hazard model for mortality by examining the troponin level which resulted in maximal improvement in model performance shown by the negative two log-likelihood ratio. Additionally, area under the curve (AUC) was examined in receiver operating characteristic (ROC) curves in a multivariable model for mortality to confirm the optimal cut-point selection. cTnT and cTnI indicate cardiac troponin T and I.
3.3 mg/L are optimal for differentiating between patients who survive and those at increased risk of dying within 5 years. These values are significantly higher than the recommendations by the Task Force, 5 similar to values that have been quoted in some studies, 2 and much less than those in other similar studies. 8, 24, 25 This illustrates the dilemma of determining a single biomarker cut-off. Peak post-operative troponin will vary depending on the population at risk, patient comorbidities, invasiveness of the procedure, underlying genetic factors, and the laboratory assay used.
Restricting the definition of PMI to dichotomized biomarker data, ignores the advantage of a quantitative assessment using a continuous measurement that examines the wide range of perioperative myocardial injury from transient and reversible, to clinically significant. Consequently, we propose that increasing levels of circulating cTnI reflect a spectrum of increasing myocardial injury, with short and long-term consequences importantly described by HLOS and mortality. Finally, although the Joint Task Force recommends the measurement of biomarker levels for 72 h post-operatively, few patients in our study (8%) had a peak cTnI occurring after POD1. There was no observed incremental value for the prediction of mortality or HLOS by measuring cTnI beyond POD1. Thus, establishing a diagnosis of PMI using only POD1 cTnI may permit more efficient use of therapeutic interventions, and thereby reduce associated morbidity and mortality. Finally, we observed no predictive value of any ECG criterion alone, or in combination with biomarker level, in contradistinction to the Task Force's recommendations.
Limitations
This study has several limitations. First, the test and validation cohorts used different components of the troponin protein complex. Despite extensive work evaluating the performance of both troponin assays in assessing the severity of myocardial injury, consensus is lacking as to the 'superior' marker. 26 Secondly, generation cTnT assays have overcome a lack of specificity with skeletal muscle cross-reactivity and higher concentrations in renal failure. 27, 28 However, the failure to calibrate platforms with standard assays for cTnI remains a significant limitation for inter-laboratory studies and clinical recommendations which rely on a dichotomous cut-off for defining significant perioperative myocardial injury. 29, 30 Thirdly, we used the well-known logistic Euroscore as an externally valid assessment of individual risk of 5-year mortality. However, the Euroscore was originally constructed to predict 1-year mortality. Fourthly, our analysis of ECG criteria was limited to the association of conventional ECG signs of PMI with mortality and HLOS, whereas the impact of arrhythmias and their relationship to the primary and secondary endpoints was not evaluated. ST-elevation was controlled for by the Marquette ECG interpretation and by the overreading cardiologists. Although acute ST-elevation may indicate PMI for an individual patient, no ECG criteria of PMI were significant on a population basis. Fifthly, our validation cohort was not constructed prospectively and thus was limited to a smaller number of perioperative covariates which therefore could not be controlled for, and may have affected our final analysis of this population. Finally, our primary endpoint of all-cause mortality does not account for cardiac-specific causes of death.
However, prior studies have demonstrated that use of all-cause mortality is equally robust to cardiac mortality, and further removes interpretation of limited death certificate information. 31, 32 Conclusion POD1 cTnI independently predicts clinically significant perioperative myocardial injury after CABG surgery, while accounting for clinical risk. ECG criteria of PMI do not independently predict mortality or HLOS, and therefore should not be included in the diagnosis of PMI after CABG surgery.
